Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.

Grandea AG 3rd, Olsen OA, Cox TC, Renshaw M, Hammond PW, Chan-Hui PY, Mitcham JL, Cieplak W, Stewart SM, Grantham ML, Pekosz A, Kiso M, Shinya K, Hatta M, Kawaoka Y, Moyle M.

Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12658-63. doi: 10.1073/pnas.0911806107. Epub 2010 Jul 1.

2.

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z, Guo Y, Yu H, Jiang S, Lone Y, Zheng BJ, Zhou Y.

Virol J. 2010 Jul 12;7:151. doi: 10.1186/1743-422X-7-151.

3.

Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.

Chen Y, Qin K, Wu WL, Li G, Zhang J, Du H, Ng MH, Shih JW, Peiris JS, Guan Y, Chen H, Xia N.

J Infect Dis. 2009 Jan 1;199(1):49-58. doi: 10.1086/594374.

PMID:
19032063
4.

A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses.

Hu H, Voss J, Zhang G, Buchy P, Zuo T, Wang L, Wang F, Zhou F, Wang G, Tsai C, Calder L, Gamblin SJ, Zhang L, Deubel V, Zhou B, Skehel JJ, Zhou P.

J Virol. 2012 Mar;86(6):2978-89. doi: 10.1128/JVI.06665-11. Epub 2012 Jan 11.

5.

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J.

PLoS One. 2008;3(12):e3942. doi: 10.1371/journal.pone.0003942. Epub 2008 Dec 16.

6.

Highly conserved sequences for human neutralization epitope on hemagglutinin of influenza A viruses H3N2, H1N1 and H5N1: Implication for human monoclonal antibody recognition.

Yamashita A, Kawashita N, Kubota-Koketsu R, Inoue Y, Watanabe Y, Ibrahim MS, Ideno S, Yunoki M, Okuno Y, Takagi T, Yasunaga T, Ikuta K.

Biochem Biophys Res Commun. 2010 Mar 19;393(4):614-8. doi: 10.1016/j.bbrc.2010.02.031. Epub 2010 Feb 10.

PMID:
20152806
7.

Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses.

Wan H, Gao J, Xu K, Chen H, Couzens LK, Rivers KH, Easterbrook JD, Yang K, Zhong L, Rajabi M, Ye J, Sultana I, Wan XF, Liu X, Perez DR, Taubenberger JK, Eichelberger MC.

J Virol. 2013 Aug;87(16):9290-300. doi: 10.1128/JVI.01203-13. Epub 2013 Jun 19.

8.

Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets.

Khurana S, Suguitan AL Jr, Rivera Y, Simmons CP, Lanzavecchia A, Sallusto F, Manischewitz J, King LR, Subbarao K, Golding H.

PLoS Med. 2009 Apr 21;6(4):e1000049. doi: 10.1371/journal.pmed.1000049. Epub 2009 Apr 21.

9.

Characterization of a fully human monoclonal antibody against extracellular domain of matrix protein 2 of influenza A virus.

Ozawa T, Jin A, Tajiri K, Takemoto M, Okuda T, Shiraki K, Kishi H, Muraguchi A.

Antiviral Res. 2011 Sep;91(3):283-7. doi: 10.1016/j.antiviral.2011.06.012. Epub 2011 Jun 25.

PMID:
21726583
10.

A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection.

Sakabe S, Iwatsuki-Horimoto K, Horimoto T, Nidom CA, Le Mt, Takano R, Kubota-Koketsu R, Okuno Y, Ozawa M, Kawaoka Y.

Antiviral Res. 2010 Dec;88(3):249-55. doi: 10.1016/j.antiviral.2010.09.007. Epub 2010 Sep 16.

11.

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.

12.

Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.

Stepanova LA, Kotlyarov RY, Kovaleva AA, Potapchuk MV, Korotkov AV, Sergeeva MV, Kasianenko MA, Kuprianov VV, Ravin NV, Tsybalova LM, Skryabin KG, Kiselev OI.

PLoS One. 2015 Mar 23;10(3):e0119520. doi: 10.1371/journal.pone.0119520. eCollection 2015.

13.

A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses.

De Marco D, Clementi N, Mancini N, Solforosi L, Moreno GJ, Sun X, Tumpey TM, Gubareva LV, Mishin V, Clementi M, Burioni R.

PLoS One. 2012;7(4):e34415. doi: 10.1371/journal.pone.0034415. Epub 2012 Apr 4.

14.

An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.

Leung HC, Chan CC, Poon VK, Zhao HJ, Cheung CY, Ng F, Huang JD, Zheng BJ.

Emerg Microbes Infect. 2015 Apr;4(4):e22. doi: 10.1038/emi.2015.22. Epub 2015 Apr 8.

15.

Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.

Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC.

J Virol. 2015 Jul;89(14):7224-34. doi: 10.1128/JVI.00585-15. Epub 2015 May 6.

16.

Development and characterization of a panel of cross-reactive monoclonal antibodies generated using H1N1 influenza virus.

Guo CY, Tang YG, Qi ZL, Liu Y, Zhao XR, Huo XP, Li Y, Feng Q, Zhao PH, Wang X, Li Y, Wang HF, Hu J, Zhang XJ.

Immunobiology. 2015 Aug;220(8):941-6. doi: 10.1016/j.imbio.2015.02.002. Epub 2015 Feb 14.

PMID:
25708705
17.

Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge.

Gao X, Wang W, Li Y, Zhang S, Duan Y, Xing L, Zhao Z, Zhang P, Li Z, Li R, Wang X, Yang P.

Antiviral Res. 2013 Apr;98(1):4-11. doi: 10.1016/j.antiviral.2013.01.010. Epub 2013 Feb 14.

PMID:
23416215
18.

[Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].

Stepanova LA, Kovaleva AA, Potapchuk MV, Korotkov AV, Kupriianov VV, Blokhina EA, Kotliarov RIu, Tsybalova LM.

Vopr Virusol. 2013 May-Jun;58(3):21-5. Russian.

PMID:
24006628
19.

Influenza A viruses: why focusing on M2e-based universal vaccines.

Ebrahimi SM, Tebianian M.

Virus Genes. 2011 Feb;42(1):1-8. doi: 10.1007/s11262-010-0547-7. Epub 2010 Nov 17. Review. Erratum in: Virus Genes. 2011 Feb;42(1):9.

PMID:
21082230
20.

Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.

Tsybalova LM, Stepanova LA, Kuprianov VV, Blokhina EA, Potapchuk MV, Korotkov AV, Gorshkov AN, Kasyanenko MA, Ravin NV, Kiselev OI.

Vaccine. 2015 Jun 26;33(29):3398-406. doi: 10.1016/j.vaccine.2015.04.073. Epub 2015 May 11.

PMID:
25976545

Supplemental Content

Support Center